Obviously it takes more than one swallow to make a summer, and obviously the moment a St.Jude Durata lead was found to have suffered the same fate as its older brother Riata, the inbound flock would be predicted by shareholders. Sure enough, one has been announced on FDA’s MAUDE database here, and sure enough the company’s share price has taken a tumble, falling 6% on the news.
Whether it’s a one-off or a sign of things to come is obviously not for us to predict, and indeed the degree of vigilance surrounding the matter means that every hair out of place will get scrutinised. St.Jude will no doubt issue a stout defence of its product, standing behind earlier claims that its more robust insulation means it won’t fail, but for the time being the company is silent on the matter.
In the meantime, in a piece of unfortunate timing for St.Jude perhaps, Cardiostim2012 is taking place in France from tomorrow, so plenty of discussion and conjecture likely. The event is the 18th running of the Cardiac Electrophysiology and Cardiac techniques congress, and one can only imagine what’s on most attendees agendas.